Literature DB >> 10509158

Analysis of Philadelphia chromosome-negative BCR-ABL-positive chronic myelogenous leukemia by hypermetaphase fluorescence in situ hybridization.

D Seong1, H M Kantarjian, M Albitar, R Arlinghaus, J Xu, M Talpaz, M B Rios, J Q Guo, S O'Brien, M Siciliano.   

Abstract

BACKGROUND: In 5%-10% of patients with of chronic myelogenous leukemia (CML), the Philadelphia chromosome (Ph) is not identified, despite the presence of the associated BCR-ABL molecular abnormality (Ph-negative, BCR-ABL-positive CML) because of sub-microscopic rearrangements. PATIENTS AND METHODS: Six patients with Ph-negative, BCR-ABL-positive CML were investigated. The Ph chromosome detection via fluorescence in situ hybridization after 24-hour mitotic arrest of bone marrow cultures resulting in several hundreds of metaphases (hypermetaphase FISH or HMF) was useful in explaining the nature of the six cases.
RESULTS: Four patients had a low frequency of Ph-positive cells by HMF (5.7%, 4.8%, 3.9%, 0.2%), i.e., a typical Ph translocation. However, two cases involved a 9q34 inserted into chromosome 22q11 (74.2% and 92%), without a deletion from chromosome 22 and reciprocal translocation onto 9, i.e., not a typical Ph translocation. The pattern of UBCR gene rearrangement was characterized by the same genomic recombination of 5-BCR and c-ABL, both in the four cases of typical translocation (9;22) and in the two cases of insertion of 9q34 into chromosome 22q11.
CONCLUSIONS: The HMF identified two different bases for Ph-negative, BCR-ABL-positive cells in CML-presence of low frequency of cells with typical Ph translocations or presence of cells with ABL insertions into the BCR gene on chromosome 22.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10509158     DOI: 10.1023/a:1008349405763

Source DB:  PubMed          Journal:  Ann Oncol        ISSN: 0923-7534            Impact factor:   32.976


  6 in total

1.  Development of a protease-resistant reporter to quantify BCR-ABL activity in intact cells.

Authors:  Angela Proctor; Imola G Zigoneanu; Qunzhao Wang; Christopher E Sims; David S Lawrence; Nancy L Allbritton
Journal:  Analyst       Date:  2016-10-17       Impact factor: 4.616

2.  Chronic myeloid leukemia with insertion-derived BCR-ABL1 fusion: redefining complex chromosomal abnormalities by correlation of FISH and karyotype predicts prognosis.

Authors:  Zhenya Tang; Gokce A Toruner; Guilin Tang; C Cameron Yin; Wei Wang; Shimin Hu; Beenu Thakral; Sa A Wang; Roberto N Miranda; Joseph D Khoury; L Jeffrey Medeiros
Journal:  Mod Pathol       Date:  2020-05-13       Impact factor: 7.842

3.  Insertion of the CCND1 gene into the IgH locus in a case of leukaemic small cell mantle lymphoma with normal chromosomes 11 and 14.

Authors:  A Aventín; J Nomdedéu; J Briones; I Espinosa; R Bordes; J Sierra
Journal:  J Clin Pathol       Date:  2003-10       Impact factor: 3.411

Review 4.  Genomic Mechanisms Influencing Outcome in Chronic Myeloid Leukemia.

Authors:  Adelina Fernandes; Naranie Shanmuganathan; Susan Branford
Journal:  Cancers (Basel)       Date:  2022-01-26       Impact factor: 6.639

5.  Nilotinib first-line therapy in patients with Philadelphia chromosome-negative/BCR-ABL-positive chronic myeloid leukemia in chronic phase: ENEST1st sub-analysis.

Authors:  Andreas Hochhaus; Franҫois-Xavier Mahon; Philipp le Coutre; Ljubomir Petrov; Jeroen J W M Janssen; Nicholas C P Cross; Delphine Rea; Fausto Castagnetti; Andrzej Hellmann; Gianantonio Rosti; Norbert Gattermann; Maria Liz Paciello Coronel; Maria Asuncion Echeveste Gutierrez; Valentin Garcia-Gutierrez; Beatrice Vincenzi; Luca Dezzani; Francis J Giles
Journal:  J Cancer Res Clin Oncol       Date:  2017-02-21       Impact factor: 4.553

6.  Prognostic significance of a normal karyotype in adult patients with BCR-ABL1-positive acute lymphoblastic leukemia in the tyrosine kinase inhibitor era.

Authors:  Ting Shi; Huanping Wang; Mixue Xie; Xueying Li; Lixia Zhu; Xiujin Ye
Journal:  Clinics (Sao Paulo)       Date:  2020-11-11       Impact factor: 2.365

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.